← Leaderboards
Thomas Richard Kosten
Yale University
$19,160,340
Attributed
$19,160,340
Total exposure
20
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.4M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$36,568,834 · 23
By mechanism
P50$20,631,975 · 8
R01$6,209,169 · 5
DP1$4,033,446 · 1
U19$2,814,713 · 5
U01$1,523,501 · 2
K05$1,266,030 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- I George Zubal$3,657,553
- Ismene L Petrakis$10,363,765
- Sherry McKee$26,885,003
- Robert T Malison$17,226,399
Others in their field
Top investigators on “Cocaine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,690,128
- Joel Gelernter · Washington University$34,364,949
- Michael A Nader · Emory University$33,226,167
- Shenghan Lai · University Of Miami Coral Gables$31,568,530
Research focus
CocaineClinical TrialsClinical ResearchDrug Abuse ChemotherapyHuman SubjectPharmaceutical PreparationsSafetyPlacebosHuman Therapy EvaluationResponseVaccinesDoseResearch PersonnelDrug AddictionLaboratoriesPharmacotherapyBaseProgramsAntibodiesMethamphetamineAntibody FormationMethadoneComorbidityToxicology
Grant awards (96)
Complementary Combination Therapy for Cocaine Dependence$387,187
R01 · FY2017 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$770,762
DP1 · FY2015 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$63,984
DP1 · FY2015 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$782,500
DP1 · FY2014 · DA · contact PI
Stimulant Pharmacotherapy: Noradrenergic Targets$837,278
P50 · FY2013 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$751,200
DP1 · FY2013 · DA · contact PI
Clinical Methods Core$319,972
P50 · FY2013 · DA · contact PI
Methadone Studies$253,852
P50 · FY2013 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$100,000
DP1 · FY2013 · DA · contact PI
Stimulant Pharmacotherapy: Noradrenergic Targets$1,257,829
P50 · FY2012 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$782,500
DP1 · FY2012 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston Treatmen$475,979
R01 · FY2012 · DA · contact PI
Clinical Methods Core$272,918
P50 · FY2012 · DA · contact PI
Methadone Studies$215,428
P50 · FY2012 · DA · contact PI
Stimulant Pharmacotherapy: Noradrenergic Targets$1,296,042
P50 · FY2011 · DA · contact PI
Human methamphetamine vaccine: Translational Avante Garde Award$782,500
DP1 · FY2011 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston Treatmen$586,910
R01 · FY2011 · DA · contact PI
Clinical Methods Core$330,461
P50 · FY2011 · DA · contact PI
Methadone Studies$243,805
P50 · FY2011 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston Treatmen$136,155
R01 · FY2011 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$4
U19 · FY2011 · DA · contact PI
Stimulant Pharmacotherapy: Noradrenergic Targets$1,335,907
P50 · FY2010 · DA · contact PI
Clinical Methods Core$270,760
P50 · FY2010 · DA · contact PI
Methadone Studies$269,672
P50 · FY2010 · DA · contact PI
Comorbidity in Cocaine and Opioid Pharmacotherapy$126,360
K05 · FY2010 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$1
U19 · FY2010 · DA · contact PI
Stimulant Pharmacotherapy: Noradrenergic Targets$1,349,323
P50 · FY2009 · DA · contact PI
Developing Immunotherapeutics for Methamphetamine Abuse$696,926
U01 · FY2009 · DA · contact PI
Methadone Studies$277,586
P50 · FY2009 · DA · contact PI
Tropisetron with Risperidone for Schizophrenia$273,900
U01 · FY2009 · MH · contact PI
Clinical Methods Core$237,623
P50 · FY2009 · DA · contact PI
Comorbidity in Cocaine and Opioid Pharmacotherapy$126,360
K05 · FY2009 · DA · contact PI
Cocaine Pharmacotherapy Targeting Dopamine & GABA$1,165,306
P50 · FY2008 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston Treatmen$478,141
R01 · FY2008 · DA · contact PI
Administrative and Scientific Core$287,886
P50 · FY2008 · DA · contact PI
Tropisetron with Risperidone for Schizophrenia$268,577
U01 · FY2008 · MH · contact PI
Comorbidity in Cocaine and Opioid Pharmacotherapy$126,360
K05 · FY2008 · DA · contact PI
Cocaine Pharmacotherapy Targeting Dopamine & GABA$1,382,814
P50 · FY2007 · DA · contact PI
Administrative and Scientific Core$462,124
P50 · FY2007 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$439,889
U19 · FY2007 · DA · contact PI
Tropisetron with Risperidone for Schizophrenia$284,098
U01 · FY2007 · MH · contact PI
Heroin Addiction Treatment: Naltrexone and Lofexidine$155,473
R01 · FY2007 · DA · contact PI
PHARMACOTHERAPIES OF COCAINE ADDICTION IN HUMANS$108,426
U19 · FY2007 · DA · contact PI
Cocaine Pharmacotherapy Targeting Dopamine & GABA$1,309,265
P50 · FY2006 · DA · contact PI
Heroin Addiction Treatment: Naltrexone and Lofexidine$297,584
R01 · FY2006 · DA · contact PI
Comorbidity in Cocaine and Opioid Pharmacotherapy$126,360
K05 · FY2006 · DA · contact PI
Cocaine Pharmacotherapy Targeting Dopamine & GABA$105,000
P50 · FY2006 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$1
U19 · FY2006 · DA · contact PI
Cocaine Pharmacotherapy Targeting Dopamine &GABA$1,338,950
P50 · FY2005 · DA
Heroin Addiction Treatment: Naltrexone and Lofexidine$232,134
R01 · FY2005 · DA
Comorbidity in Cocaine and Opioid Pharmacotherapy$126,360
K05 · FY2005 · DA
Heroin Addiction Treatment: Naltrexone and Lofexidine$63,850
R01 · FY2005 · DA
Cocaine Pharmacotherapy Targeting Dopamine &GABA$28,016
P50 · FY2005 · DA
Kappa Opioid Antagonist for Cocaine Addiction$1
U19 · FY2005 · DA
Cocaine Pharmacotherapy Targeting Dopamine &GABA$1,198,230
P50 · FY2004 · DA
Pharmacotherapy for opioid and cocaine dependence$462,886
R01 · FY2004 · DA
Scientific and Administrative Core$449,907
P50 · FY2004 · DA
Cocaine Vaccine for Methadone Maintained Patients$427,742
R01 · FY2004 · DA
Heroin Addiction Treatment: Naltrexone and Lofexidine$213,699
R01 · FY2004 · DA
COMORBIDITY IN COCAINE AND OPIOID PHARMACOTHERAPY$126,846
K05 · FY2004 · DA
Cocaine Vaccine for Methadone Maintained Patients$83,688
R01 · FY2004 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$946,778
P50 · FY2003 · DA
Pharmacotherapy for opioid and cocaine dependence$449,610
R01 · FY2003 · DA
Cocaine Vaccine for Methadone Maintained Patients$416,756
R01 · FY2003 · DA
COMORBIDITY IN COCAINE AND OPIOID PHARMACOTHERAPY$126,846
K05 · FY2003 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$32,390
P50 · FY2003 · DA
Cocaine Vaccine for Methadone Maintained Patients$23,875
R01 · FY2003 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$15,134
P50 · FY2003 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$996,212
P50 · FY2002 · DA
Pharmacotherapy for opioid and cocaine dependence$437,185
R01 · FY2002 · DA
Cocaine Vaccine for Methadone Maintained Patients$324,096
R01 · FY2002 · DA
ACTIVE IMMUNIZATION TO DEVELOP ANTIBODIES TO COCAINE$171,205
U19 · FY2002 · DA
IMMUNOLOGICAL AGENTS FOR COCAINE ABUSE$171,205
U19 · FY2002 · DA
COMORBIDITY IN COCAINE AND OPIOID PHARMACOTHERAPY$126,846
K05 · FY2002 · DA
THERAPEUTIC COCAINE VACCINE$121,660
U19 · FY2002 · DA
CORE--MEDICATION DEVELOPMENT RESEARCH CENTER$0
P50 · FY2002 · DA
CLOPIDOGREL &ISRADIPINE FOR BRIAN PERFUSION DEFECTS IN COCAINE ABUSERS$0
P50 · FY2002 · DA
fMRI of Gender and Stress Response in Cocaine Dependence$0
P50 · FY2002 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$931,447
P50 · FY2001 · DA
Pharmacotherapy for opioid and cocaine dependence$367,568
R01 · FY2001 · DA
COMORBIDITY IN COCAINE AND OPIOID PHARMACOTHERAPY$126,846
K05 · FY2001 · DA
11TH - 15TH ANNUAL MEETINGS AND SYMPOSIA$45,000
R13 · FY2001 · DA
CORE--MEDICATION DEVELOPMENT RESEARCH CENTER$0
P50 · FY2001 · DA
CLOPIDOGREL &ISRADIPINE FOR BRIAN PERFUSION DEFECTS IN COCAINE ABUSERS$0
P50 · FY2001 · DA
COCAINE PHARMACOTHERAPIES FOR COMORBID POPULATIONS$892,560
P50 · FY2000 · DA
THERAPEUTIC COCAINE VACCINE$744,249
U19 · FY2000 · DA
IMMUNOLOGICAL AGENTS FOR COCAINE ABUSE$295,779
U19 · FY2000 · DA
ACTIVE IMMUNIZATION TO DEVELOP ANTIBODIES TO COCAINE$295,779
U19 · FY2000 · DA
BUPRENORPHINE MAINTENANCE FOR OPIOID ADDICTS$188,651
R01 · FY2000 · DA
ACTIVE IMMUNIZATION TO DEVELOP ANTIBODIES TO COCAINE$171,205
U19 · FY2000 · DA
IMMUNOLOGICAL AGENTS FOR COCAINE ABUSE$171,205
U19 · FY2000 · DA
CLOPIDOGREL &ISRADIPINE FOR BRIAN PERFUSION DEFECTS IN COCAINE ABUSERS$160,750
P50 · FY2000 · DA
CORE--MEDICATION DEVELOPMENT RESEARCH CENTER$160,750
P50 · FY2000 · DA
COMORBIDITY IN COCAINE AND OPIOID PHARMACOTHERAPY$126,846
K05 · FY2000 · DA
THERAPEUTIC COCAINE VACCINE$124,104
U19 · FY2000 · DA
11TH - 15TH ANNUAL MEETINGS AND SYMPOSIA$45,000
R13 · FY2000 · DA